What is the price-to-earnings ratio of Mabpharm?
The price-earnings ratio of Mabpharm is currently -10.24.
Mabpharm P/E 2024
Mabpharm P/E
-10.24
Ticker
2181.HK
ISIN
KYG5780F1046
As of Oct 15, 2024, Mabpharm's P/E ratio was -10.24, a -18.21% change from the -12.52 P/E ratio recorded in the previous year.
The Mabpharm P/E history
Mabpharm Aktienanalyse
What does Mabpharm do?
Mabpharm Ltd is a biopharmaceutical company based in Suzhou, China. The company was founded in 2009 and specializes in the development and production of monoclonal antibodies. The business model of Mabpharm is to develop, produce, and sell high-quality biological drugs worldwide. The company works closely with customers to understand their needs and provide customized solutions. Mabpharm is divided into different divisions, each specialized in producing specific products. The main ones are oncology, immunology, cardiology, and infectious diseases. Each division offers a portfolio of products tailored to the needs of patients. In the field of oncology, Mabpharm offers a range of monoclonal antibodies that can be used to treat cancer. This includes therapies for breast cancer, gastric cancer, colorectal cancer, and lung cancer. The products have all been developed in collaboration with renowned partners worldwide and undergo rigorous clinical testing before being brought to market. Mabpharm's immunology division focuses on developing drugs for the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The products in this division have been specifically designed to regulate the immune system and suppress inflammation symptoms. The cardiology division of Mabpharm is dedicated to the development of drugs for the prevention and treatment of cardiovascular diseases. The products include antibodies for the treatment of lipid metabolism disorders and blood clots. Mabpharm's cardiovascular products also include a cholesterol-lowering medication that helps prevent heart attacks and strokes. In the infectious diseases division, Mabpharm has developed products for the treatment of hepatitis B and hepatitis C. These can reduce viral load and improve liver function. Furthermore, Mabpharm is also involved in the development of vaccines against COVID-19. Mabpharm has become a leading provider of monoclonal antibodies and biological drugs in China and internationally. The company works closely with academics and researchers to find innovative solutions and stay up to date with the latest scientific advancements. In conclusion, Mabpharm is an innovative company specializing in the research and development of biological drugs of all kinds. The company has a wide range of products that have been developed to meet the needs of patients worldwide. Mabpharm has emerged as a key player in the global market for biological drugs in recent years and is a company to watch when it comes to the future of biotechnology. Mabpharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering Mabpharm's P/E Ratio
The Price to Earnings (P/E) Ratio of Mabpharm is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing Mabpharm's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of Mabpharm is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in Mabpharm’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about Mabpharm stock
How has the price-earnings ratio of Mabpharm changed compared to last year?
The price-to-earnings ratio of Mabpharm has increased by -18.21% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Mabpharm high compared to other companies?
Yes, the price-to-earnings ratio of Mabpharm is high compared to other companies.
How does an increase in the price-earnings ratio of Mabpharm affect the company?
An increase in the price-earnings ratio of Mabpharm would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Mabpharm affect the company?
A decrease in the price-earnings ratio of Mabpharm would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Mabpharm?
Some factors that influence the price-earnings ratio of Mabpharm are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Mabpharm pay?
Over the past 12 months, Mabpharm paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mabpharm is expected to pay a dividend of 0 CNY.
What is the dividend yield of Mabpharm?
The current dividend yield of Mabpharm is .
When does Mabpharm pay dividends?
Mabpharm pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mabpharm?
Mabpharm paid dividends every year for the past 0 years.
What is the dividend of Mabpharm?
For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mabpharm located?
Mabpharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mabpharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mabpharm from 10/15/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/15/2024.
When did Mabpharm pay the last dividend?
The last dividend was paid out on 10/15/2024.
What was the dividend of Mabpharm in the year 2023?
In the year 2023, Mabpharm distributed 0 CNY as dividends.
In which currency does Mabpharm pay out the dividend?
The dividends of Mabpharm are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mabpharm
Our stock analysis for Mabpharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mabpharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
